;PMID: 10477671
;source_file_825.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..34] = [t:0..34]
;1)sentence:[e:40..159] = [t:40..159]
;2)section:[e:163..304] = [t:163..304]
;3)section:[e:308..385] = [t:308..385]
;4)sentence:[e:389..496] = [t:389..496]
;5)sentence:[e:497..584] = [t:497..584]
;6)sentence:[e:585..661] = [t:585..661]
;7)sentence:[e:662..792] = [t:662..792]
;8)sentence:[e:793..1050] = [t:793..1050]
;9)sentence:[e:1051..1216] = [t:1051..1216]
;10)sentence:[e:1217..1288] = [t:1217..1288]
;11)sentence:[e:1289..1421] = [t:1289..1421]
;12)sentence:[e:1422..1479] = [t:1422..1479]
;13)sentence:[e:1481..1578] = [t:1481..1578]
;14)sentence:[e:1579..1673] = [t:1579..1673]
;15)sentence:[e:1674..1765] = [t:1674..1765]
;16)sentence:[e:1766..1876] = [t:1766..1876]
;17)sentence:[e:1877..1925] = [t:1877..1925]
;18)sentence:[e:1926..2115] = [t:1926..2115]
;19)section:[e:2119..2164] = [t:2119..2164]

;section 0 Span:0..34
;Front Biosci. 1999 Sep 1;4:A16-25.
(SEC
  (FRAG (NNP:[0..5] Front) (NNP:[6..12] Biosci) (.:[12..13] .)
        (CD:[14..18] 1999) (CC:[19..22] Sep) (CD:[23..26] 1;4)
        (CD:[26..30] :A16) (HYPH:[30..31] -) (CD:[31..33] 25) (.:[33..34] .)))

;sentence 1 Span:40..159
;Role of CYP2E1 in the pathogenesis of alcoholic liver disease: modifications
;by  cAMP and ubiquitin-proteasome pathway.
;[48..54]:cyp450:"CYP2E1"
;[121..125]:substance:"cAMP"
;[130..139]:substance:"ubiquitin"
;[140..150]:substance:"proteasome"
(SENT
  (NP-HLN
    (NP
      (NP (NN:[40..44] Role))
      (PP (IN:[45..47] of)
        (NP (NN:[48..54] CYP2E1)))
      (PP (IN:[55..57] in)
        (NP
          (NP (DT:[58..61] the) (NN:[62..74] pathogenesis))
          (PP (IN:[75..77] of)
            (NP (JJ:[78..87] alcoholic) (NN:[88..93] liver)
                (NN:[94..101] disease))))))
    (::[101..102] :)
    (NP
      (NP (NNS:[103..116] modifications))
      (PP (IN:[117..119] by)
        (NP
          (NP (NN:[121..125] cAMP))
          (CC:[126..129] and)
          (NP
            (NML (NN:[130..139] ubiquitin) (HYPH:[139..140] -)
                 (NN:[140..150] proteasome))
            (NN:[151..158] pathway)))))
    (.:[158..159] .)))

;section 2 Span:163..304
;Gouillon ZQ, Miyamoto K, Donohue TM, Wan YJ, French BA, Nagao Y, Fu P, Reitz
;RC,  Hagbjork A, Yap C, Yuan QX, Ingelman-Sundberg M, French SW.
(SEC
  (FRAG (NNP:[163..171] Gouillon) (NNP:[172..174] ZQ) (,:[174..175] ,)
        (NNP:[176..184] Miyamoto) (NNP:[185..186] K) (,:[186..187] ,)
        (NNP:[188..195] Donohue) (NNP:[196..198] TM) (,:[198..199] ,)
        (NNP:[200..203] Wan) (NNP:[204..206] YJ) (,:[206..207] ,)
        (NNP:[208..214] French) (NNP:[215..217] BA) (,:[217..218] ,)
        (NNP:[219..224] Nagao) (NNP:[225..226] Y) (,:[226..227] ,)
        (NNP:[228..230] Fu) (NNP:[231..232] P) (,:[232..233] ,)
        (NNP:[234..239] Reitz) (NNP:[240..242] RC) (,:[242..243] ,)
        (NNP:[245..253] Hagbjork) (NNP:[254..255] A) (,:[255..256] ,)
        (NNP:[257..260] Yap) (NNP:[261..262] C) (,:[262..263] ,)
        (NNP:[264..268] Yuan) (NNP:[269..271] QX) (,:[271..272] ,)
        (NNP:[273..281] Ingelman) (HYPH:[281..282] -) (JJ:[282..290] Sundberg)
        (NNP:[291..293] M,) (NNP:[294..300] French) (NNP:[301..304] SW.)))

;section 3 Span:308..385
;Department of Pathology, Harbor-UCLA Medical Center, Torrance, CA 90509,
;USA.
(SEC
  (FRAG (NNP:[308..318] Department) (IN:[319..321] of)
        (NNP:[322..331] Pathology) (,:[331..332] ,) (NNP:[333..339] Harbor)
        (HYPH:[339..340] -) (NNP:[340..344] UCLA) (NNP:[345..352] Medical)
        (NNP:[353..359] Center) (,:[359..360] ,) (NNP:[361..369] Torrance)
        (,:[369..370] ,) (NNP:[371..373] CA) (CD:[374..379] 90509)
        (,:[379..380] ,) (NNP:[381..384] USA) (.:[384..385] .)))

;sentence 4 Span:389..496
;The ethanol inducible isoform of cytochrome P450, CYP2E1, may play a role in 
;ethanol-induced liver injury.
;[393..400]:substance:"ethanol"
;[411..418]:cyp450:"isoform"
;[422..437]:cyp450:"cytochrome P450"
;[439..445]:cyp450:"CYP2E1"
;[467..474]:substance:"ethanol"
(SENT
  (S
    (NP-SBJ
      (NP
        (NP (DT:[389..392] The)
          (ADJP (NN:[393..400] ethanol) (JJ:[401..410] inducible))
          (NN:[411..418] isoform))
        (PP (IN:[419..421] of)
          (NP (NN:[422..432] cytochrome) (NN:[433..437] P450))))
      (,:[437..438] ,)
      (NP (NN:[439..445] CYP2E1)))
    (,:[445..446] ,)
    (VP (MD:[447..450] may)
      (VP (VB:[451..455] play)
        (NP (DT:[456..457] a) (NN:[458..462] role))
        (PP (IN:[463..465] in)
          (NP
            (ADJP (NN:[467..474] ethanol) (HYPH:[474..475] -)
                  (VBN:[475..482] induced))
            (NN:[483..488] liver) (NN:[489..495] injury)))))
    (.:[495..496] .)))

;sentence 5 Span:497..584
;Therefore, the factors which govern CYP2E1  degradation and turnover were
;investigated.
;[533..539]:cyp450:"CYP2E1"
(SENT
  (S
    (ADVP (RB:[497..506] Therefore))
    (,:[506..507] ,)
    (NP-SBJ-1
      (NP (DT:[508..511] the) (NNS:[512..519] factors))
      (SBAR
        (WHNP-2 (WDT:[520..525] which))
        (S
          (NP-SBJ-2 (-NONE-:[525..525] *T*))
          (VP (VBP:[526..532] govern)
            (NP
              (NP
                (NML-3 (NN:[533..539] CYP2E1))
                (NN:[541..552] degradation))
              (CC:[553..556] and)
              (NP
                (NML-3 (-NONE-:[556..556] *P*))
                (NN:[557..565] turnover)))))))
    (VP (VBD:[566..570] were)
      (VP (VBN:[571..583] investigated)
        (NP-1 (-NONE-:[583..583] *))))
    (.:[583..584] .)))

;sentence 6 Span:585..661
;These factors include cAMP,  ubiquitin, proteasomal enzymes and CYP2E1 mRNA.
;[607..611]:substance:"cAMP"
;[614..623]:substance:"ubiquitin"
;[625..644]:substance:"proteasomal enzymes"
;[649..660]:substance:"CYP2E1 mRNA"
(SENT
  (S
    (NP-SBJ (DT:[585..590] These) (NNS:[591..598] factors))
    (VP (VBP:[599..606] include)
      (NP
        (NP (NN:[607..611] cAMP))
        (,:[611..612] ,)
        (NP (NN:[614..623] ubiquitin))
        (,:[623..624] ,)
        (NP (JJ:[625..636] proteasomal) (NNS:[637..644] enzymes))
        (CC:[645..648] and)
        (NP (NN:[649..655] CYP2E1) (NN:[656..660] mRNA))))
    (.:[660..661] .)))

;sentence 7 Span:662..792
;Rats fed ethanol or pair-fed  isocaloric dextrose were pair-fed with rats fed
;ethanol or dextrose treated with  cAMP for 2 months.
;[671..678]:substance:"ethanol"
;[703..711]:substance:"dextrose"
;[740..747]:substance:"ethanol"
;[751..759]:substance:"dextrose"
;[774..778]:substance:"cAMP"
;[783..784]:quantitative-value:"2"
;[785..791]:quantitative-units:"months"
(SENT
  (S
    (NP-SBJ-1
      (NP (NNS:[662..666] Rats))
      (VP (VBN:[667..670] fed)
        (NP (-NONE-:[670..670] *))
        (NP
          (NP (NN:[671..678] ethanol))
          (CC:[679..681] or)
          (NP
            (ADJP (NN:[682..686] pair) (HYPH:[686..687] -) (VBN:[687..690] fed))
            (JJ:[692..702] isocaloric) (NN:[703..711] dextrose)))))
    (VP (VBD:[712..716] were)
      (VP (NN:[717..721] pair) (HYPH:[721..722] -) (VBN:[722..725] fed)
        (NP-1 (-NONE-:[725..725] *))
        (PP (IN:[726..730] with)
          (NP
            (NP (NNS:[731..735] rats))
            (VP
              (VP (VBN:[736..739] fed)
                (NP (-NONE-:[739..739] *))
                (NP
                  (NP (NN:[740..747] ethanol))
                  (CC:[748..750] or)
                  (NP
                    (NP (NN:[751..759] dextrose))
                    (VP (VBN:[760..767] treated)
                      (NP (-NONE-:[767..767] *))
                      (PP (IN:[768..772] with)
                        (NP (NN:[774..778] cAMP))))))))))
        (PP-TMP (IN:[779..782] for)
          (NP (CD:[783..784] 2) (NNS:[785..791] months)))))
    (.:[791..792] .)))

;sentence 8 Span:793..1050
;The liver pathology, regenerative activity, fatty acid  composition, NFkappaB
;activation, ubiquitin conjugates and proteasomal enzymes  were measured as
;were the apoprotein levels of CYP2E1, CYP3A, CYP4A and mRNA  levels for
;CYP2E1 and ubiquitin expression.
;[837..847]:substance:"fatty acid"
;[862..870]:substance:"NFkappaB"
;[883..903]:substance:"ubiquitin conjugates"
;[908..927]:substance:"proteasomal enzymes"
;[955..965]:substance:"apoprotein"
;[976..982]:cyp450:"CYP2E1"
;[984..989]:cyp450:"CYP3A"
;[991..996]:cyp450:"CYP4A"
;[1001..1005]:substance:"mRNA"
;[1018..1024]:cyp450:"CYP2E1"
;[1029..1038]:substance:"ubiquitin"
(SENT
  (S
    (NP-SBJ-3 (DT:[793..796] The)
      (NML
        (NML
          (NML-2 (NN:[797..802] liver))
          (NN:[803..812] pathology))
        (,:[812..813] ,)
        (NML
          (NML-2 (-NONE-:[813..813] *P*))
          (JJ:[814..826] regenerative) (NN:[827..835] activity))
        (,:[835..836] ,)
        (NML
          (NML-2 (-NONE-:[836..836] *P*))
          (NML (JJ:[837..842] fatty) (NN:[843..847] acid))
          (NN:[849..860] composition))
        (,:[860..861] ,)
        (NML
          (NML-2 (-NONE-:[861..861] *P*))
          (NN:[862..870] NFkappaB) (NN:[871..881] activation))
        (,:[881..882] ,)
        (NML
          (NML-2 (-NONE-:[882..882] *P*))
           (NN:[883..892] ubiquitin) (NNS:[893..903] conjugates))
        (CC:[904..907] and)
        (NML
          (NML-2 (-NONE-:[907..907] *P*))
           (JJ:[908..919] proteasomal) (NNS:[920..927] enzymes))))
    (VP (VBD:[929..933] were)
      (VP (VBN:[934..942] measured)
        (NP-3 (-NONE-:[942..942] *))
        (SBAR-ADV (IN:[943..945] as)
          (SINV (VBD:[946..950] were)
            (NP-SBJ
              (NP
                (NP (DT:[951..954] the) (NN:[955..965] apoprotein)
                    (NNS:[966..972] levels))
                (PP (IN:[973..975] of)
                  (NP (NN:[976..982] CYP2E1) (,:[982..983] ,)
                      (NN:[984..989] CYP3A) (,:[989..990] ,)
                      (NN:[991..996] CYP4A))))
              (CC:[997..1000] and)
              (NP
                (NP (NN:[1001..1005] mRNA) (NNS:[1007..1013] levels))
                (PP (IN:[1014..1017] for)
                  (NP
                    (NP (NN:[1018..1024] CYP2E1)
                      (NML-1 (-NONE-:[1024..1024] *P*)))
                    (CC:[1025..1028] and)
                    (NP (NN:[1029..1038] ubiquitin)
                      (NML-1 (NN:[1039..1049] expression)))))))
            (VP (-NONE-:[1049..1049] *?*))))))
    (.:[1049..1050] .)))

;sentence 9 Span:1051..1216
;The results showed, that the cAMP  treatment ameliorated the increase liver
;fat storage and changes in the fatty  acid composition in the livers of
;ethanol fed rats.
;[1080..1084]:substance:"cAMP"
;[1158..1169]:substance:"fatty  acid"
;[1199..1206]:substance:"ethanol"
(SENT
  (S
    (NP-SBJ (DT:[1051..1054] The) (NNS:[1055..1062] results))
    (VP (VBD:[1063..1069] showed) (,:[1069..1070] ,)
      (SBAR (IN:[1071..1075] that)
        (S
          (NP-SBJ (DT:[1076..1079] the) (NN:[1080..1084] cAMP)
                  (NN:[1086..1095] treatment))
          (VP (VBD:[1096..1107] ameliorated)
            (NP
              (NP (DT:[1108..1111] the) (NN:[1112..1120] increase)
                  (NN:[1121..1126] liver) (NN:[1127..1130] fat)
                  (NN:[1131..1138] storage))
              (CC:[1139..1142] and)
              (NP
                (NP (NNS:[1143..1150] changes))
                (PP (IN:[1151..1153] in)
                  (NP (DT:[1154..1157] the)
                    (NML (JJ:[1158..1163] fatty) (NN:[1165..1169] acid))
                    (NN:[1170..1181] composition)))))
            (PP-LOC (IN:[1182..1184] in)
              (NP
                (NP (DT:[1185..1188] the) (NNS:[1189..1195] livers))
                (PP (IN:[1196..1198] of)
                  (NP
                    (ADJP (NN:[1199..1206] ethanol) (VBN:[1207..1210] fed))
                    (NNS:[1211..1215] rats)))))))))
    (.:[1215..1216] .)))

;sentence 10 Span:1217..1288
;Other histologic features of  alcoholic liver disease were not changed.
(SENT
  (S
    (NP-SBJ-1
      (NP (JJ:[1217..1222] Other) (JJ:[1223..1233] histologic)
          (NNS:[1234..1242] features))
      (PP (IN:[1243..1245] of)
        (NP (JJ:[1247..1256] alcoholic) (NN:[1257..1262] liver)
            (NN:[1263..1270] disease))))
    (VP (VBD:[1271..1275] were) (RB:[1276..1279] not)
      (VP (VBN:[1280..1287] changed)
        (NP-1 (-NONE-:[1287..1287] *))))
    (.:[1287..1288] .)))

;sentence 11 Span:1289..1421
;Western blot quantitation showed that  the amount of ubiquitin and ubiquitin
;conjugates were markedly reduced by  ethanol treatment.
;[1342..1351]:substance:"ubiquitin"
;[1356..1376]:substance:"ubiquitin conjugates"
;[1403..1410]:substance:"ethanol"
(SENT
  (S
    (NP-SBJ
      (NML (JJ:[1289..1296] Western) (NN:[1297..1301] blot))
      (NN:[1302..1314] quantitation))
    (VP (VBD:[1315..1321] showed)
      (SBAR (IN:[1322..1326] that)
        (S
          (NP-SBJ-1
            (NP (DT:[1328..1331] the) (NN:[1332..1338] amount))
            (PP (IN:[1339..1341] of)
              (NP
                (NP (NN:[1342..1351] ubiquitin))
                (CC:[1352..1355] and)
                (NP (NN:[1356..1365] ubiquitin) (NNS:[1366..1376] conjugates)))))
          (VP (VBD:[1377..1381] were)
            (ADVP (RB:[1382..1390] markedly))
            (VP (VBN:[1391..1398] reduced)
              (NP-1 (-NONE-:[1398..1398] *))
              (PP (IN:[1399..1401] by)
                (NP-LGS (NN:[1403..1410] ethanol) (NN:[1411..1420] treatment))))))))
    (.:[1420..1421] .)))

;sentence 12 Span:1422..1479
;Similarly, ethanol decreased the level of ubiquitin mRNA.
;[1433..1440]:substance:"ethanol"
;[1464..1478]:substance:"ubiquitin mRNA"
(SENT
  (S
    (ADVP (RB:[1422..1431] Similarly))
    (,:[1431..1432] ,)
    (NP-SBJ (NN:[1433..1440] ethanol))
    (VP (VBD:[1441..1450] decreased)
      (NP
        (NP (DT:[1451..1454] the) (NN:[1455..1460] level))
        (PP (IN:[1461..1463] of)
          (NP (NN:[1464..1473] ubiquitin) (NN:[1474..1478] mRNA)))))
    (.:[1478..1479] .)))

;sentence 13 Span:1481..1578
;cAMP ameliorated the inhibition of the proteasomal enzyme proteolysis caused
;by  ethanol feeding.
;[1481..1485]:substance:"cAMP"
;[1520..1538]:substance:"proteasomal enzyme"
;[1562..1569]:substance:"ethanol"
(SENT
  (S
    (NP-SBJ (NN:[1481..1485] cAMP))
    (VP (VBD:[1486..1497] ameliorated)
      (NP
        (NP
          (NP (DT:[1498..1501] the) (NN:[1502..1512] inhibition))
          (PP (IN:[1513..1515] of)
            (NP (DT:[1516..1519] the)
              (NML (JJ:[1520..1531] proteasomal) (NN:[1532..1538] enzyme))
              (NN:[1539..1550] proteolysis))))
        (VP (VBN:[1551..1557] caused)
          (NP (-NONE-:[1557..1557] *))
          (PP (IN:[1558..1560] by)
            (NP-LGS (NN:[1562..1569] ethanol) (NN:[1570..1577] feeding))))))
    (.:[1577..1578] .)))

;sentence 14 Span:1579..1673
;The ethanol-induced increase in the CYP2E1 protein was  partially inhibited
;by cAMP treatment.
;[1583..1590]:substance:"ethanol"
;[1615..1629]:cyp450:"CYP2E1 protein"
;[1658..1662]:substance:"cAMP"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[1579..1582] The)
        (ADJP (NN:[1583..1590] ethanol) (HYPH:[1590..1591] -)
              (VBN:[1591..1598] induced))
        (NN:[1599..1607] increase))
      (PP (IN:[1608..1610] in)
        (NP (DT:[1611..1614] the)
           (NN:[1615..1621] CYP2E1) (NN:[1622..1629] protein))))
    (VP (VBD:[1630..1633] was)
      (ADVP (RB:[1635..1644] partially))
      (VP (VBN:[1645..1654] inhibited)
        (NP-1 (-NONE-:[1654..1654] *))
        (PP (IN:[1655..1657] by)
          (NP-LGS (NN:[1658..1662] cAMP) (NN:[1663..1672] treatment)))))
    (.:[1672..1673] .)))

;sentence 15 Span:1674..1765
;cAMP treatment decreased CYP2E1 mRNA  levels in both ethanol-fed and pair fed
;control rats.
;[1674..1678]:substance:"cAMP"
;[1699..1710]:substance:"CYP2E1 mRNA"
;[1727..1734]:substance:"ethanol"
(SENT
  (S
    (NP-SBJ (NN:[1674..1678] cAMP) (NN:[1679..1688] treatment))
    (VP (VBD:[1689..1698] decreased)
      (NP
        (NML (NN:[1699..1705] CYP2E1) (NN:[1706..1710] mRNA))
        (NNS:[1712..1718] levels))
      (PP-LOC (IN:[1719..1721] in)
        (NP (CC:[1722..1726] both)
          (NP
            (ADJP (NN:[1727..1734] ethanol) (HYPH:[1734..1735] -)
                  (VBN:[1735..1738] fed))
            (NML-1 (-NONE-:[1738..1738] *P*)))
          (CC:[1739..1742] and)
          (NP
            (ADJP (NN:[1743..1747] pair) (VBN:[1748..1751] fed))
            (NML-1 (NN:[1752..1759] control) (NNS:[1760..1764] rats))))))
    (.:[1764..1765] .)))

;sentence 16 Span:1766..1876
;Likewise NFkappaB  activation was not increased by ethanol but cAMP reduced
;the level of NFkappaB  activation.
;[1775..1783]:substance:"NFkappaB"
;[1817..1824]:substance:"ethanol"
;[1829..1833]:substance:"cAMP"
;[1855..1863]:substance:"NFkappaB"
(SENT
  (S
    (S
      (ADVP (RB:[1766..1774] Likewise))
      (NP-SBJ-1 (NN:[1775..1783] NFkappaB) (NN:[1785..1795] activation))
      (VP (VBD:[1796..1799] was) (RB:[1800..1803] not)
        (VP (VBN:[1804..1813] increased)
          (NP-1 (-NONE-:[1813..1813] *))
          (PP (IN:[1814..1816] by)
            (NP-LGS (NN:[1817..1824] ethanol))))))
    (CC:[1825..1828] but)
    (S
      (NP-SBJ (NN:[1829..1833] cAMP))
      (VP (VBD:[1834..1841] reduced)
        (NP
          (NP (DT:[1842..1845] the) (NN:[1846..1851] level))
          (PP (IN:[1852..1854] of)
            (NP (NN:[1855..1863] NFkappaB) (NN:[1865..1875] activation))))))
    (.:[1875..1876] .)))

;sentence 17 Span:1877..1925
;CAMP treatment also reduced CYP4A but not CYP3A.
;[1877..1881]:substance:"CAMP"
;[1905..1910]:cyp450:"CYP4A"
;[1919..1924]:cyp450:"CYP3A"
(SENT
  (S
    (NP-SBJ (NN:[1877..1881] CAMP) (NN:[1882..1891] treatment))
    (ADVP (RB:[1892..1896] also))
    (VP
      (VP (VBD:[1897..1904] reduced)
        (NP=1 (NN:[1905..1910] CYP4A)))
      (CC:[1911..1914] but)
      (VP (RB:[1915..1918] not)
        (NP=1 (NN:[1919..1924] CYP3A))))
    (.:[1924..1925] .)))

;sentence 18 Span:1926..2115
;The results support  the concept that cAMP treatment partially protects the
;liver from  ethanol-induced fatty liver by reducing CYP2E1 induction through
;cAMP's effects  on CYP2E1 synthesis.
;[1964..1968]:substance:"cAMP"
;[2014..2021]:substance:"ethanol"
;[2054..2060]:cyp450:"CYP2E1"
;[2079..2083]:substance:"cAMP"
;[2098..2104]:cyp450:"CYP2E1"
(SENT
  (S
    (NP-SBJ (DT:[1926..1929] The) (NNS:[1930..1937] results))
    (VP (VBP:[1938..1945] support)
      (NP (DT:[1947..1950] the) (NN:[1951..1958] concept)
        (SBAR (IN:[1959..1963] that)
          (S
            (NP-SBJ (NN:[1964..1968] cAMP) (NN:[1969..1978] treatment))
            (ADVP (RB:[1979..1988] partially))
            (VP (VBZ:[1989..1997] protects)
              (NP (DT:[1998..2001] the) (NN:[2002..2007] liver))
              (PP (IN:[2008..2012] from)
                (NP
                  (ADJP (NN:[2014..2021] ethanol) (HYPH:[2021..2022] -)
                        (VBN:[2022..2029] induced))
                  (JJ:[2030..2035] fatty) (NN:[2036..2041] liver)))
              (PP-MNR (IN:[2042..2044] by)
                (S-NOM
                  (NP-SBJ (-NONE-:[2044..2044] *))
                  (VP (VBG:[2045..2053] reducing)
                    (NP (NN:[2054..2060] CYP2E1) (NN:[2061..2070] induction))
                    (PP (IN:[2071..2078] through)
                      (NP
                        (NP
                          (NP (NN:[2079..2083] cAMP) (POS:[2083..2085] 's))
                          (NNS:[2086..2093] effects))
                        (PP (IN:[2095..2097] on)
                          (NP (NN:[2098..2104] CYP2E1)
                              (NN:[2105..2114] synthesis)))))))))))))
    (.:[2114..2115] .)))

;section 19 Span:2119..2164
;PMID: 10477671 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2119..2123] PMID) (::[2123..2124] :) (CD:[2125..2133] 10477671)
        (-LRB-:[2134..2135] -LSB-) (NNP:[2135..2141] PubMed)
        (HYPH:[2142..2143] -) (NN:[2144..2151] indexed) (IN:[2152..2155] for)
        (NNP:[2156..2163] MEDLINE) (-RRB-:[2163..2164] -RSB-)))
